Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levosalbutamol.

D Ormrod1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Levosalbutamol, a pure beta(2)-adrenoceptor agonist, offers asthma symptom relief comparable to salbutamol. It may provide a superior risk/benefit profile by avoiding the inactive (S)-enantiomer potentially linked to airway hyperreactivity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Lanoteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Salbutamol, a racemic beta(2)-adrenoceptor agonist, contains an inactive (S)-enantiomer.
  • The (S)-enantiomer of salbutamol may be associated with increased airway hyperreactivity in asthma patients.
  • Levosalbutamol is the R-enantiomer, developed to provide therapeutic effects without potential adverse effects of the S-enantiomer.

Purpose of the Study:

  • To evaluate the efficacy and safety of levosalbutamol compared to racemic salbutamol.
  • To determine if levosalbutamol offers an improved risk/benefit ratio for asthma symptom control.
  • To assess the bronchodilatory and bronchoprotective effects of levosalbutamol.

Main Methods:

  • Pharmacodynamic and pharmacokinetic profiling of levosalbutamol.

Related Experiment Videos

  • Assessment of bronchoprotective effects using methacholine challenge.
  • A large clinical trial evaluating inhaled levosalbutamol (0.625mg or 1.25mg TID) for asthma symptom relief.

    • Main Results:

    • Levosalbutamol demonstrated similar pharmacodynamic and pharmacokinetic profiles to racemic salbutamol.
    • Levosalbutamol exhibited bronchoprotective effects post-methacholine challenge.
    • Inhaled levosalbutamol (0.625mg or 1.25mg TID) effectively relieved asthma symptoms, with 0.625mg being as effective as 2.5mg racemic salbutamol.

    Conclusions:

    • Levosalbutamol provides effective asthma symptom relief with a well-tolerated safety profile.
    • The risk/benefit ratio of levosalbutamol is considered superior to racemic salbutamol.
    • Levosalbutamol represents a potentially improved therapeutic option for asthma management.